Education
About Us
Working with TipRanks
Follow Us
Bausch + Lomb Corporation (BLCO)
NYSE:BLCO
RESEARCH TOOLSreports
BLCO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.45 - $21.69
Previous CloseN/A
Volume107.99K
Average Volume (3M)998.11K
Market Cap
$4.06B
Enterprise Value$11.05B
Total Cash (Recent Filing)$202.00M
Total Debt (Recent Filing)$4.83B
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Jul 30, 2025EPS Estimate
0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding353,396,640
10 Day Avg. Volume1,164,653
30 Day Avg. Volume998,105
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap2.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.81
Enterprise Value/Ebitda27.69
Forecast
1Y Price Target
$15.30Price Target Upside33.04% Upside
Rating ConsensusHold
Number of Analyst Covering11
---
Bulls Say, Bears Say
Bulls Say
Product DemandMIEBO's weekly prescriptions grew 98% YoY to 20,086 in 1Q25.
Product LaunchELIOS, the MIGS glaucoma surgery product using excimer laser technology has launched in the EU, anticipating U.S. approval YE2025 and an early 2026 launch.
Revenue GuidanceManagement raised 2025 revenue guidance to $5.0-$5.1B (up 4.5-6.5% ex-fx) from $4.95-$5.05B, lowering adjusted EBITDA to $850-$900M from $900M-$950M (vs. consensus’s $916M).
Bears Say
Financial PerformanceAdjusted EBITDA of $126M (ex-IPRD) declined 28% y/y, falling below consensus’s $163M, operating margins compressed to 5.7% from 11.7% y/y (versus consensus’s 8.9%), with an EPS loss of $0.07 below consensus’s $0.02.
Product RecallThe enVista recall negatively impacts revenue and EBITDA in 2025, despite the issue being resolved and production resuming.
Tariff ImpactThere is uncertainty surrounding potential tariff impacts, which could further affect the company's financial guidance.
---
Ownership Overview
0.52% Insiders
0.32% Mutual Funds
0.02% Other Institutional Investors
99.04% Public Companies and
Individual Investors
BLCO FAQ
What was Bausch + Lomb Corporation’s price range in the past 12 months?
Bausch + Lomb Corporation lowest stock price was $10.45 and its highest was $21.69 in the past 12 months.
What is Bausch + Lomb Corporation’s market cap?
Bausch + Lomb Corporation’s market cap is $4.06B.
When is Bausch + Lomb Corporation’s upcoming earnings report date?
Bausch + Lomb Corporation’s upcoming earnings report date is Jul 30, 2025 which is in 87 days.
How were Bausch + Lomb Corporation’s earnings last quarter?
Bausch + Lomb Corporation released its earnings results on Apr 30, 2025. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of $0.021 by -$0.091.
Is Bausch + Lomb Corporation overvalued?
According to Wall Street analysts Bausch + Lomb Corporation’s price is currently Undervalued.
Does Bausch + Lomb Corporation pay dividends?
Bausch + Lomb Corporation does not currently pay dividends.
What is Bausch + Lomb Corporation’s EPS estimate?
Bausch + Lomb Corporation’s EPS estimate is 0.1.
How many shares outstanding does Bausch + Lomb Corporation have?
Bausch + Lomb Corporation has 353,396,640 shares outstanding.
What happened to Bausch + Lomb Corporation’s price movement after its last earnings report?
Bausch + Lomb Corporation reported an EPS of -$0.07 in its last earnings report, missing expectations of $0.021. Following the earnings report the stock price went down -15.743%.
Which hedge fund is a major shareholder of Bausch + Lomb Corporation?
Currently, no hedge funds are holding shares in BLCO
---
Bausch + Lomb Corporation Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$15.30 (33.04% Upside)
$15.30 (33.04% Upside)
Blogger Sentiment
Bullish
BLCO Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 7.1%
Last 30 Days ▲ 7.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.64%
12-Months-Change
Fundamentals
Return on Equity
-5.56%
Trailing 12-Months
Asset Growth
0.20%
Trailing 12-Months
Company Description
Bausch + Lomb Corporation
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
---
BLCO Company Deck
---
BLCO Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted robust growth in the Vision Care and Surgical segments, as well as strong performance from the MIEBO product line. However, challenges in the Pharmaceuticals segment, a recall of enVista IOLs, and potential tariff impacts posed significant concerns. Despite these challenges, the company's diverse portfolio and proactive measures indicate resilience.Read More>---
BLCO Stock 12 Month Forecast
Average Price Target
$15.30
▲(33.04% Upside)
Technical Analysis
---